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The vitamin K-dependent g-glutamyl carboxylase cat-
alyzes the modification of specific glutamates in a num-
ber of proteins required for blood coagulation and asso-
ciated with bone and calcium homeostasis. All known
vitamin K-dependent proteins possess a conserved eigh-
teen-amino acid propeptide sequence that is the pri-
mary binding site for the carboxylase. We compared the
relative affinities of synthetic propeptides of nine hu-
man vitamin K-dependent proteins by determining the
inhibition constants (Ki) toward a factor IX propeptide/
g-carboxyglutamic acid domain substrate. The Ki values
for six of the propeptides (factor X, matrix Gla protein,
factor VII, factor IX, PRGP1, and protein S) were be-
tween 2–35 nM, with the factor X propeptide having the
tightest affinity. In contrast, the inhibition constants for
the propeptides of prothrombin and protein C are ;100-
fold weaker than the factor X propeptide. The propep-
tide of bone Gla protein demonstrates severely impaired
carboxylase binding with an inhibition constant of at
least 200,000-fold weaker than the factor X propeptide.
This study demonstrates that the affinities of the
propeptides of the vitamin K-dependent proteins vary
over a considerable range; this may have important
physiological consequences in the levels of vitamin K-
dependent proteins and the biochemical mechanism by
which these substrates are modified by the carboxylase.
The vitamin K-dependent carboxylase catalyzes the post-
translational modification of specific glutamates to g-carboxy-
glutamate (Gla)1 in a number of proteins. Most vitamin K-de-
pendent proteins are involved in the hemostatic process
(prothrombin, factors VII, IX, and X, and proteins C, S, and Z),
whereas two others (bone Gla protein and matrix Gla protein)
are associated with bone (1–4). Two new putative vitamin
K-dependent proteins of unassigned function, proline-rich Gla
proteins (PRGP1 and PRGP2), were identified by sequence
homology searches and are believed to be membrane proteins
(5).
A conserved eighteen-amino acid sequence essential for sub-
strate recognition is found in all vitamin K-dependent proteins
and was first identified by Pan and Price (6) based on sequence
comparisons of the blood and bone vitamin K-dependent pro-
teins. The conserved region is present as a propeptide sequence
amino-terminal to the highly conserved Gla domains of the
vitamin K-dependent blood proteins and is proteolytically re-
moved to form the mature protein. With bone Gla protein, this
sequence is also present as a propeptide amino-terminal to the
mature form of the protein, whereas with matrix Gla protein
the vitamin K-dependent propeptide-like sequence is part of
the mature form of the protein (7). Confirmation of the impor-
tance of the propeptide sequence in carboxylation is demon-
strated by experiments where deletion of the propeptide abro-
gates carboxylation of factor IX or protein C expressed in cell
culture (8, 9). In addition, mutagenesis studies have identified
a number of highly conserved amino acids (e.g. Phe 216, Ala
210, Leu 26) as well as less conserved positions (217 and 215)
whose mutation affects carboxylation. (8, 10–12). Glutamate-
containing peptides with covalently linked propeptides have
1000-fold lower Km values than similar peptides without the
propeptide sequence and are competitively inhibited by free
propeptide (13). A peptide containing the propeptide and Gla
domain of factor IX (FIXproGLA) has a sub-micromolar Km for
the carboxylase and can be fully carboxylated in a processive
manner (14, 15).
There is significant evidence that the vitamin K-dependent
propeptide sequence is the primary binding site for the carbox-
ylase. The decarboxylated mature forms of the vitamin K-de-
pendent blood proteins (i.e. without the propeptide sequence)
(16, 17) or the Gla domains themselves (18) are poor substrates
for the carboxylase. In addition, the propeptide attached to
normally uncarboxylated glutamate-containing peptides are
multiply carboxylated both in vivo and in vitro (18, 19). Pep-
tides containing the factor IX propeptide followed by factor IX
Gla domain, the rest of the factor IX sequence, or a random
glutamate containing sequence have similar Km values for the
carboxylase (18). Therefore, the propeptide of the vitamin K-
dependent proteins appears to confer the perceived affinity of
the carboxylase for its substrate with little or no contribution
from other domains. An exception to this may be with the
vitamin K-dependent bone Gla protein in which an attached
propeptide is not necessary for efficient binding to the
carboxylase (18, 20–22).
Since the importance of the propeptide sequence in vitamin
K-dependent carboxylation was first identified based on the
presence of highly conserved residues at specific positions, it
has been assumed that the propeptides form similar structures
and therefore bind the carboxylase with similar affinities. A
previous study has questioned this assumption (23), but a
systematic comparison of the relative affinities has not been
reported. Therefore, we determined the relative affinities of the
propeptides of nine vitamin K-dependent proteins by competi-
tive inhibition of a factor IX propeptide/Gla domain substrate.
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Previously, these comparisons could not be performed because
of the presence of endogenous substrates in mammalian micro-
somal preparations of the enzyme or contamination by free
propeptide used to elute the affinity purified carboxylase.
Therefore, these studies were performed using carboxylase pu-
rified by a metal-ion dependent antibody from recombinant
insect cells which do not contain vitamin K-dependent proteins
and are free of endogenous substrates (24). We find that the
inhibition constants of most of the propeptides vary over a
100-fold range and the propeptide of bone Gla protein has
severely reduced carboxylase binding affinity. Because varia-
tions in amino acid sequences of the highly conserved propep-
tide sequences must confer the varied affinities, such studies
should provide insights into which amino acids within the
propeptide are important for carboxylase recognition. In addi-
tion, the variation in affinities of the propeptides may have
important physiological consequences in affecting the levels of
vitamin K-dependent proteins in vivo and the biochemical
mechanism by which these proteins are modified by the
carboxylase.
EXPERIMENTAL PROCEDURES
Materials—All chemicals were reagent grade. Peptides based on the
propeptide sequences (Fig. 2) of the human vitamin K-dependent pro-
teins were chemically synthesized, purified by reverse phase high per-
formance liquid chromatography and verified to be correct by ion spray
mass spectrometry by Chiron Technologies (Clayton Victoria, Austra-
lia). The concentrations of all peptides were determined by amino acid
analysis. The FIXproGLA (R-4Q, R-1S) peptide was prepared as de-
scribed previously (14). The insect cell expression vector (pVL1392) was
purchased from Pharmingen (San Diego, CA), and the baculovirus viral
DNA (BacVector 3000) was purchased from Novagen (Madison, WI).
The Sf9 cells (Spodoptera frugiperda) were obtained from the Linebur-
ger Cancer Center at the University of North Carolina-Chapel Hill, and
the High Five cells (Trichoplusia ni) were a gift from Dr. Thomas Kost
of Glaxo-Wellcome Inc. (Research Triangle Park, NC). The HPC4 anti-
body affinity resin was provided by Dr. Charles T. Esmon (Oklahoma
Medical Research Foundation, Oklahoma City, OK). The FLAG anti-
body and FLAG peptide standards were purchased from Sigma.
Expression of r-Carboxylase in High Five Cells—The cDNA encoding
the human vitamin K-dependent carboxylase was sub-cloned into the
EcoRI site of the pVL1392 vector. The sequence coding for the FLAG
antibody epitope (DYKDDDDK) was introduced at the amino-terminal
end of the carboxylase, and a HPC4 antibody tag (EDQVDPRLIDGK)
(26) was added at the carboxyl-terminal end. The engineered vector was
cotransfected with baculovirus BacVector 3000 triple-cut virus DNA
into Sf9 cells. Recombinant virus was isolated by plaque purification,
amplified, and titered by plaque assay according to the instructions of
the manufacturer (27). Expression of carboxylase was done by infection
of ;2 3 106/ml High Five cells with the recombinant virus at a muti-
plicity of infection of ;1. Cells were collected after 48 h by centrifuga-
tion and stored at 280 °C.
Preparation of Microsomes from High Five Cells—A total of 1.8 3 109
cells from 1.2 liters of culture expressing the recombinant human car-
boxylase were washed twice with Buffer A (20 mM phosphate (pH 7.4),
150 mM NaCl, 13 protease inhibitor mixture (28) and 10% glycerol) and
resuspended in 50 ml of Buffer A. The sample was homogenized by 15
strokes with a Dounce homogenizer and then sonicated with four 5-s
pulses using a Ultrasonic Heat Systems sonicator. Cellular debris was
removed by centrifugation at 4000 3 g for 15 min, and the supernatant
was centrifuged at 105,000 3 g for 1 h. The microsomal pellet was
resuspended in 20 mM phosphate (pH 7.4), 500 mM NaCl, 13 protease
inhibitor mixture, and 10% glycerol and stored at 280 °C.
Purification of r-Carboxylase Using HPC4 Antibody Resin—Micro-
somes were diluted to a final protein concentration of 12 mg/ml and
solubilized by the addition of an equal volume of solubilization buffer
(50 mM Tris (pH 7.4), 0.15 M NaCl, 1% CHAPS and 0.2% phosphatidyl-
choline, 10% glycerol, and 13 PIC mixture) at 4 °C for 1 h. The solubi-
lized microsomes were centrifuged at 105,000 3 g for 1 h, and the pellet
was discarded. A total of 10 ml of HPC4 resin was equilibrated with
wash buffer (20 mM Tris (pH 7.4), 0.15 M NaCl, 0.5% CHAPS and 0.2%
phosphatidylcholine, 13 protease inhibitor mixture) and added to the
solubilization supernatant along with a final concentration of 5 mM
CaCl2 and incubated overnight with gentle stirring. The resin was
centrifuged and poured into a column, washed with 50 ml of wash buffer
plus 5 mM CaCl2, and eluted with wash buffer plus 10 mM EDTA.
Carboxylase samples were collected, aliquoted, and stored at 270 °C.
Concentration of enzyme was estimated from dot blots of carboxylase
using the anti-FLAG antibody and known concentrations of FLAG
peptide standards.
Carboxylase Assays—The inhibition constants (Ki) for the various
propeptides were determined from the ability of the propeptides to
inhibit carboxylation of the FIXproGLA substrate. Purified recombi-
nant carboxylase (;40 nM final concentration) was mixed on ice with a
final concentration of 25 mM MOPS (pH 7.4), 0.5 M NaCl, 0.28% CHAPS,
0.12% phosphatidylcholine, 222 mM vitamin K hydroquinone, 6 mM
dithiothreitol, and 5 mCi of NaH14CO3 (specific activity, 54 mCi/mmol;
ICN Corp). Aliquots of this mixture were added to an indicated final
concentration of propeptide and FIXproGLA peptide. Reactions were
transferred to a 20 °C water bath and incubated for 1 h. Reactions were
stopped by the addition of 75 ml of 1 N NaOH, and the total amount of
14CO2 incorporation was determined as described previously (23). The
background 14CO2 incorporation in the absence of the substrate was
subtracted from each assay point. This background averaged ,1 nM/
min compared with 0.6 nM/min observed in the absence of vitamin K
and was unaffected by the propeptide concentrations used in our assays
except as noted with the factor VII propeptide. Data for inhibition of
varied concentrations of the FIXproGLA substrate by set concentra-
tions of the factor IX, factor X, and prothrombin propeptides were fit by
numerical integration using the program Dynafit2 (29) to determine the
most likely inhibition mechanism and estimates of the kinetic param-
eters. Values for the inhibition constant (Ki) for each propeptide were
determined by fitting the data for inhibition of a set concentration of the
FIXproGLA substrate (0.5 mM) with each propeptide by nonlinear re-
gression to the equation for tight binding competitive inhibition (Equa-
tion 1) where: Ki* is the apparent inhibition constant, It is the total
propeptide concentration, Et is the total carboxylase concentration, and




Î~Ki* 1 It 2 Et!2 1 4Ki*Et
2 ~Ki* 1 It 2 Et! (Eq. 1)
Ki 5
Ki*
S1 1 @FIXproGLA#Km D
All Ki values are reported as the average of at least three independ-
ent determinations 6 S.D. For the factor VII propeptide, an equation
(Equation 2) was derived using the rapid equilibrium assumption based
on the mechanism in Scheme 1 which accounts for carboxylation of the
propeptide itself.




























The purpose of this study was to compare the relative affin-
ities of the propeptides of nine vitamin K-dependent proteins
for the vitamin K-dependent g-glutamyl-carboxylase. These
studies were conducted with recombinant human vitamin K-
dependent carboxylase expressed in insect cells and purified by
a metal ion-dependent antibody to an engineered epitope tag.
Therefore this carboxylase preparation is free of endogenous
2 Available on the World Wide Web at http://www.biokin.com.
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substrates or free propeptide required for purification of car-
boxylase from liver.
We first looked at the ability of the factor IX, factor X, and
prothrombin propeptides to inhibit the carboxylation of varied
concentrations of a factor IX propeptide/Gla domain substrate.
As can be seen in Fig. 1, each of the propeptides inhibits
carboxylation of the FIXproGLA peptide, although signifi-
cantly different concentrations of propeptide are required to
achieve similar levels of inhibition. Because the apparent inhi-
bition constants for the factor IX and factor X propeptides are
within the range of the enzyme concentration used in the
assays, these propeptides appear to be tight-binding inhibitors
of the carboxylase, and the inhibition constants cannot be de-
termined by simple inhibition kinetics. Therefore, data were fit
by numerical integration using the program Dynafit (29) to
various plausible mechanisms for inhibition by the propeptides
(i.e. competitive, non-competitive, mixed etc). For all three
propeptides (Fig. 1), best-fits were achieved by a competitive
inhibition mechanism with affinity constants for factor X (Ki 5
1.3 6 0.4 nM), factor IX (Ki 5 16 6 3.1 nM), and prothrombin (Ki
5 270 6 50 nM). The inhibition data are consistent with free
propeptide being a competitive inhibitor of FIXproGLA carbox-
ylation as seen previously with attached propeptide substrates
(13, 18). The significant differences in the Ki values for the
factor X, factor IX, and prothrombin propeptides indicate that
these propeptides possess very different apparent affinities for
the carboxylase.
To compare the relative affinities of the vitamin K-depend-
ent propeptides for the carboxylase, we determined the inhibi-
tion constants for nine propeptides by competitive inhibition of
a propeptide/Gla domain substrate (FIXproGLA) carboxylation
with increasing concentrations of a given propeptide. The se-
quence and Ki value for each peptide are summarized in Fig. 2.
As noted previously, the propeptides appear to be tight binding
inhibitors of the carboxylase, therefore data (Fig. 3) were fit to
equations (Equation 1) appropriate for this kind of inhibition
(30). As can be seen in Figs. 2 and 3, the relative affinities of the
vitamin K-dependent propeptides vary over a significant range.
The propeptide of factor X has the tightest affinity (Ki 5 2.6 nM)
followed by matrix Gla protein (Ki 5 5.8 nM). The propeptides
of protein S (Ki 5 12.3 nM) and PRGP1 (Ki 5 12.8) are in the
same range followed by factor IX (Ki 5 33.6 nM). PRGP1 is a
putative vitamin K-dependent protein that was identified by
homology searches based on the highly conserved Gla domain
sequence motifs of the vitamin K-dependent proteins (5). How-
ever, it is not known whether this protein is actually carbox-
ylated. Because the Ki of the PRGP1 propeptide is within the
range observed for the known carboxylated vitamin K-depend-
ent proteins and the propeptide is all that is required to direct
carboxylation of an adjacent glutamate containing region (18,
19), the PRGP1 precursor likely is able to bind and be modified
by the vitamin K-dependent carboxylase.
An unusual phenomenon is observed with the factor VII
propeptide when it is used as an inhibitor in the competition
assays. As seen in Fig. 4A, increasing concentrations of the
factor VII propeptide reduce the carboxylase activity to a point,
but at higher concentrations the activity increases. When the
inhibitor (factor VII propeptide) is varied in the absence of the
FIXproGLA substrate, a concentration-dependent increase in
carboxylation is observed (Fig. 4A). Small glutamate-contain-
ing peptides without covalently linked propeptides are com-
monly used as substrates for the carboxylase and are carboxyl-
ated at much higher rates than substrates with attached
propeptides (31). The factor VII propeptide, unlike the other
vitamin K-dependent propeptides, contains a di-glutamate pair
and appears to be acting as a glutamate substrate for the
carboxylase. Apparent carboxylation of the factor IX propep-
tide, which contains a single glutamate, is also observed, albeit
at a significantly lower level than that of the factor VII propep-
tide. However, at the concentrations of propeptides used in our
assays, incorporation of radioactive CO2 into these propeptides
did not affect our Ki determinations (Fig. 4A, inset). There is no
apparent incorporation of radioactive CO2 into the propeptides
FIG. 1. Effect of factor X, factor IX, and prothrombin propep-
tides on FIXproGLA carboxylation. A, effect of 0 nM (l), 50 nM (f),
and 200 nM (Œ) factor IX propeptide on FIXproGLA carboxylation. Lines
were drawn according to Equation 1 with Et 5 38 nM, Km 5 62 6 14 nM,
kcat 5 0.30 6 0.02 min
21, and Ki 5 16 6 3.1 nM. B, effect of 0 nM (l), 20
nM (f), and 80 nM ([trif) factor X propeptide on FIXproGLA carboxyla-
tion. Lines were drawn according to Equation 1 with Et 5 38 nM, Km 5
57 6 14 nM, kcat 5 0.3 6 0.02 min
21, and Ki 5 1.3 6 0.4 nM. C, effect of
0 nM (l), 5000 nM (f), 2500 nM (Œ), and 625 nM (l) prothrombin
propeptide on FIXproGLA carboxylation. Lines were drawn according
to Equation 1 with Et 5 38 nM, Km 5 74 6 19 nM, kcat 5 0.33 6 0.02
min21, and Ki 5 270 6 50 nM.
FIG. 2. Sequences of synthetic peptides and their inhibition
constants. Sequences are based on the propeptides of the indicated
human vitamin K-dependent proteins. Inhibition constants toward
FIXproGLA carboxylation are determined as described under “Experi-
mental Procedures” and are reported as the average of at least three
independent determinations 6 S.D.
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of prothrombin and matrix Gla protein, which do not contain
glutamates (Fig. 4A, inset). These observations suggest that
amino acids surrounding a particular glutamate may greatly
influence its affinity for the carboxylase active site and that
glutamate pairs in particular have higher affinity for the car-
boxylase active site as has been noted previously (32). Because
these results indicate that the propeptide binding site and
glutamate active site of the carboxylase can be occupied by
separate factor VII propeptide molecules, we analyzed the data
for inhibition by the factor VII propeptide using an equation
(Equation 2) derived from a mechanism (Scheme 1) that ac-
counts for the carboxylation of the propeptide itself. This anal-
ysis yields an estimate for the Ki 5 11.1 6 0.8 nM. To further
validate the estimate of the Ki for the factor VII propeptide, we
also analyzed the effect of the factor VII propeptide on varying
concentrations of the FIXproGLA propeptide (Fig. 4B). The
concentrations of the factor VII propeptide used in this exper-
iment are well below the concentrations at which it demon-
strates background activity. The value of the Ki from this
experiment is 5.7 6 0.8 nM, similar to the value obtained by
analysis of varying propeptide at one substrate concentration
(Fig. 4A). Although it is possible that the factor VII propeptide
is carboxylated in vivo, this observation is likely a consequence
of the high concentrations of propeptide used in these inhibi-
tion assays. Nevertheless, this phenomena does demonstrate
the concept that amino acids surrounding a particular gluta-
mate can significantly affect its carboxylation.
In contrast to the other propeptides, we were unable to
measure significant inhibition using the bone Gla protein
propeptide. We observe less than 10% inhibition by 400 mM
bone Gla protein propeptide, therefore it must have signifi-
cantly weaker affinity (Ki . 500 mM) than that observed for the
other propeptides. The bone Gla propeptide is the only known
vitamin K-dependent propeptide sequence that contains a gly-
cine at the highly conserved position 210. A previous study has
shown that substitution of glycine in place of alanine at posi-
tion 210 in a factor IX propeptide/Gla domain peptide in-
creases its Km for the carboxylase 30-fold (23). Therefore this
alteration may be at least partially responsible for the severely
reduced affinity of the bone Gla propeptide. Studies have
shown that decarboxylated bone Gla protein without a co-
valently attached propeptide is an excellent substrate for the
carboxylase (18, 20–22) although a covalently attached propep-
tide is required for efficient carboxylation of the vitamin K-de-
pendent blood clotting proteins (8, 9, 16, 17). Therefore, the
bone Gla protein substrate has a very weak propeptide but
appears to have a strong binding site within its Gla domain,
whereas the vitamin K-dependent blood proteins have strong
propeptides but weak binding sites within their Gla domains
This suggests the possibility that bone Gla protein and the
blood coagulation proteins may have separate mechanisms for
substrate recognition. Interestingly, the Ki for the propeptide-
like sequence in the other known vitamin K-dependent bone
protein, matrix Gla protein, appears to be in the same range as
the blood clotting proteins. Therefore the weak affinity of the
bone Gla protein propeptide is not characteristic of the vitamin
K-dependent bone proteins. Whether the propeptide plays a
role in the carboxylation of bone Gla protein will require fur-
ther investigation.
The comparisons of the relative affinities of the vitamin
K-dependent proteins in this study show that the affinities of
most of the vitamin K-dependent propeptides vary over a 10-
fold range. Two propeptides (prothrombin and protein C) have
significantly weaker affinities, and the propeptide of bone Gla
protein is at least 200,000-fold weaker than the factor X
propeptide. The physiological importance and consequences of
the broad range of propeptide affinities are unclear. For the
vitamin K-dependent blood coagulation proteins, the propep-
tide is essential for substrate recognition and binding of the
carboxylase. Vitamin K-dependent carboxylation proceeds
through a processive mechanism in which multiple glutamic
acid residues can be modified in a single binding event (15).
Therefore vitamin K-dependent carboxylation proceeds
FIG. 3. Inhibition of FIXproGLA carboxylation by propeptides
of various vitamin K-dependent propeptides. The effect of the
various propeptides on the carboxylation of 0.5 mM factor IX propeptide/
Gla domain peptide are shown. Data were normalized to the carboxyl-
ation of the FIXproGLA peptide in the absence of propeptide. Propep-
tides used are as follows: factor X (l), matrix Gla protein (E), protein S
(3), PRGP1 (f), factor IX (M), prothrombin (Œ), protein C (‚), and bone
Gla protein (ƒ).
FIG. 4. Inhibition of FIXproGla carboxylation by factor VII
propeptide. A, the effect of varying concentrations of factor VII
propeptide (Œ) or matrix Gla protein propeptide (‚) on the carboxyla-
tion of 0.5 mM FIX proGLA is shown. The line for factor VII propeptide
in the presence of FIXproGLA was drawn according to Equation 2 using
Vmax1 5 11 6 1.3 nM/min, Vmax2 5 733 6 47 nM/min, Km 5 60 nM, Kglu
5 2900 mM, and Ki 5 11 6 0.8 nM. The carboxylation of the factor VII
propeptide (M) in the absence of the FIXproGLA peptide is also shown.
Inset, background carboxylation with varying concentrations of propep-
tides of matrix Gla protein (M), prothrombin (‚), factor IX (Œ), and
factor VII (l) in the absence of FIXproGLA substrate. B, inhibition of
various concentrations of FIXproGLA by 0 nM (l), 20 nM (Œ), and 80 nM
(f) factor VII propeptide. Lines were drawn using Equation 1 with kcat
5 0.29 6 0.01 min21, Et 5 38 nM, Km 5 60 6 7.6 nM, and Ki 5 5.7 6 0.8
nM.
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through a multi-step pathway in which multiple binding inter-
actions and/or catalytic steps may contribute to the perceived
affinity of the substrate for the carboxylase; nevertheless, the
critical role of the propeptide in substrate recognition suggests
that the binding affinity of the propeptide for the carboxylase
should significantly affect the binding of the entire substrate.
Two in vivo studies provide evidence for variation in the
affinities of the vitamin K-dependent blood coagulation pro-
teins for the carboxylase. De Metz et al. (34) have found that
liver microsomes from warfarin-treated cows accumulate un-
carboxylated precursors of prothrombin, factor IX, and factor X.
Although the prothrombin precursor would be expected to be
present at higher concentrations, 69% of the carboxylase was
complexed with factor X precursors, whereas 21% was associ-
ated with prothrombin and 8% with factor IX (34). Further
evidence for the high affinity of the propeptide of factor X for
the carboxylase is that warfarin treatment of HepG2 cells
increases the level of factor X associated with the carboxylase
with a concomitant decrease in the amount of prothrombin
associated with the carboxylase (25). In a cell line that does not
express factor X, no such competition was observed, and the
authors ascribe this phenomena to a reduced affinity of the
prothrombin precursor compared with that of factor X precur-
sors. Both of these studies are consistent with our observation
that factor X propeptide has a significantly higher affinity for
the carboxylase than the prothrombin propeptide, and there-
fore the observed variations in affinities of the propeptides can
impact the binding of the entire vitamin K-dependent protein
substrates.
Patients with mutations in the factor IX propeptide demon-
strate marked clinical effects, which demonstrates the physio-
logical importance of propeptide affinity. Propeptide mutations
in factor IX that increase the Km of the substrate for the
carboxylase cause an unusual sensitivity to warfarin in several
patients (23, 33). Without warfarin treatment, these patients
demonstrate normal or near-normal factor IX activity, but the
factor IX activity is depressed below 1% upon warfarin admin-
istration, well below the range observed for the other vitamin
K-dependent factors. This indicates that reduced propeptide
binding affects the level of a particular vitamin K-dependent
protein. Regulation of the levels of vitamin K-dependent pro-
teins should be subordinate to a number of factors such as
transcription levels and relative protein stability. Neverthe-
less, the observed competition of the factor X and prothrombin
substrates for the carboxylase and the clinical consequences of
factor IX propeptide mutations suggest that the significant
variations in the affinities of the vitamin K-dependent propep-
tides may also have a significant role in determining the levels
of these proteins.
This work provides the first extensive study of the relative
affinities of the vitamin K-dependent propeptides for the car-
boxylase. Despite the sequence similarities observed for all the
propeptides, there is a wide variation in the observed affinities
of the propeptides for the carboxylase. Further work will be
required to ascertain the structural determinants of these vari-
able affinities and the physiological consequences of these
observations.
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